Tricuspid regurgitation (TR) is a common valvular pathology and is associated with significant morbidity and mortality. However, there is no currently defined optimal management strategy: medical therapy is limited to diuretics, and tricuspid valve surgery is rarely performed and associated with high risks. This has led to the emergence of numerous transcatheter therapies that are showing promising early results but are faced with multiple challenges. The tricuspid valve anatomy is complex and variable, imaging of tricuspid valve by echocardiography can be difficult, and current grading of TR severity and right ventricular size and function is mostly subjective. Also, the optimal timing of the intervention and appropriate selection of patients who will benefit remain topics of debate with limited supporting data. In this review, we present the current challenges and considerations in patients' selection and propose a trial design and selection criteria aimed to address these limitations.
Keywords: Patient selection; Transcatheter tricuspid valve intervention; Tricuspid regurgitation.
Copyright © 2019 Elsevier Inc. All rights reserved.